Compare TPCS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TPCS | BOLD |
|---|---|---|
| Founded | 1956 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 36.5M |
| IPO Year | 2008 | 2024 |
| Metric | TPCS | BOLD |
|---|---|---|
| Price | $3.52 | $1.41 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.00 |
| AVG Volume (30 Days) | 23.6K | ★ 67.2K |
| Earning Date | 02-17-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 64.20 | 32.47 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $34,031,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.72 | N/A |
| 52 Week Low | $2.88 | $0.96 |
| 52 Week High | $6.25 | $1.68 |
| Indicator | TPCS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 32.22 | 45.14 |
| Support Level | $3.40 | $1.12 |
| Resistance Level | $4.01 | $1.53 |
| Average True Range (ATR) | 0.15 | 0.05 |
| MACD | -0.05 | -0.01 |
| Stochastic Oscillator | 7.50 | 15.77 |
Techprecision Corp manufactures metal fabricated and machined precision components and systems. It offers a full range of services required to transform raw materials into precision finished products. The company's products are used in markets including defense, aerospace, nuclear, medical, and precision industries. All of its operations and customers are located in the United States. The company have two wholly owned subsidiaries that are each reportable segments: Ranor and Stadco. Each reportable segment focuses on the manufacture and assembly of specific components. It derives maximum revenue from Ranor segment.
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.